Safety and efficacy of MD1003 in patients with progressive multiple sclerosis


  • MD1003 treatment did not significantly improve disability or walking speed in patients with progressive multiple sclerosis (MS). In addition, high biotin serum concentrations can cause interference of laboratory tests; therefore, due to safety concerns and lack of efficacy, MD1003 is not recommended for treatment of progressive MS.

Why this matters

    All approved treatments for MS target the immune system; however, progressive MS may not be mediated by immunological activity only. Previous studies have shown a lack of significant effect of immunological drugs, such as natalizumab, in patients with progressive MS. MD1003 is a high-dose form of biotin which targets mitochondrial dysfunction, a hallmark of progressive MS. Therefore, it is important to understand the safety and efficacy of MD1003 in patients with this disease.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.